nach oben

Erschienen in:

22.06.2020 | Preclinical study

High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer

verfasst von: Yoshiya Horimoto, Noriko Sasahara, Ritsuko Sasaki, May Thinzar Hlaing, Asumi Sakaguchi, Harumi Saeki, Atsushi Arakawa, Takanori Himuro, Mitsue Saito

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Multi-gene expression assays have been developed with the aim of predicting late recurrence in patients with estrogen receptor (ER)-positive breast cancer. However, establishment of alternative markers based on immunohistochemistry is also important for achieving practical use. Based on our previous study, forkhead box A1 (FOXA1) protein was tested as a potentially useful predictive marker for late recurrence.

Methods

117 patients with ER-positive HER2-negative invasive breast cancer who developed distant metastasis following curative surgery were retrospectively investigated. We also evaluated responsiveness to endocrine therapy according to FOXA1 expression. Furthermore, publicly available mRNA microarray data were analyzed to examine patterns of metastasis according to FOXA1 mRNA expression, employing the Kaplan–Meier plotter.

Results

High expression of FOXA1 was an independent factor predicting long disease-free survival (DFS), along with small tumor size (p = 0.010 and 0.016, respectively). Discrimination of DFS was improved by combining these two factors, i.e., patients with FOXA1-high small tumors had the longest DFS while those with FOXA1-low large tumors had the shortest DFS. Moreover, we revealed that risk of distant metastasis started to increase after the completion of adjuvant endocrine therapy in patients with FOXA1-high tumors.

Conclusion

Among patients who developed distant metastasis, those with FOXA1-high tumors had significantly longer DFS. We believe our data to raise the possibility of FOXA1 being a useful predictive marker for late recurrence and to provide new insights into the biology of FOXA1-high breast cancers.

Nur mit Berechtigung zugänglich

Smith GL (2014) The long and short of tamoxifen therapy: a review of the ATLAS trial. J Adv Pract Oncol 5:57–60PubMedPubMedCentral

Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375:209–219CrossRef

Mamounas EP, Bandos H, Lembersky BC, Jeong J-H, Geyer CE, Rastogi P et al (2019) Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:88–99CrossRef

Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA et al (2019) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 37:423–438CrossRef

Cuzick J (2019) Predicting late recurrence in ER-positive breast cancer. Nat Rev Clin Oncol 16:406–408CrossRef

Foldi J, O’Meara T, Marczyk M, Sanft T, Silber A, Pusztai L (2019) Defining risk of late recurrence in early-stage estrogen receptor-positive breast cancer: clinical versus molecular tools. J Clin Oncol 37:1365–1369CrossRef

Yamashita H, Ogiya A, Shien T, Horimoto Y, Masuda N, Inao T et al (2016) Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer 23:830–843CrossRef

Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R et al (2014) The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res 20:1298–1305CrossRef

Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW et al (2013) Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 105:1504–1511CrossRef

10.

Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B et al (2013) Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 14:1067–1076CrossRef

11.

Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM et al (2013) Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst 105:1036–1042CrossRef

12.

Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z et al (2019) Prediction of distant recurrence using endopredict among women with ER⁺, HER²⁻ node-positive and node-negative breast cancer treated with endocrine therapy only. Clin Cancer Res 25:3865–3872CrossRef

13.

Buus R, Yeo B, Brentnall AR, Klintman M, Cheang MCU, Khabra K et al (2018) Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer. Breast Cancer Res 20:103–103CrossRef

14.

Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167CrossRef

15.

Jerevall PL, Ma XJ, Li H, Salunga R, Kesty NC, Erlander MG et al (2011) Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 104:1762–1769CrossRef

16.

Jansen MPHM, Sieuwerts AM, Look MP, Ritstier K, Gelder MEM, Staveren IL et al (2007) HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol. 25:662–668CrossRef

17.

Jerevall P-L, Brock J, Palazzo J, Wieczorek T, Misialek M, Guidi AJ et al (2019) Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score. Breast Cancer Res Treat 173:375–383CrossRef

18.

An X, Xu F, Luo R, Zheng Q, Lu J, Yang Y et al (2018) The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer. BMC Cancer 18:331CrossRef

19.

Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ et al (2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122:33–43CrossRef

20.

Ademuyiwa FO, Thorat MA, Jain RK, Nakshatri H, Badve S (2009) Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Mod Pathol 23:270CrossRef

21.

Wolf I, Bose S, Williamson EA, Miller CW, Karlan BY, Koeffler HP (2007) FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer 120:1013–1022CrossRef

22.

Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS et al (2008) Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol 61:327–332CrossRef

23.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM et al (2007) FOXA1 expression in breast cancer—correlation with luminal subtype A and survival. Clin Cancer Res 13:4415–4421CrossRef

24.

Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS (2010) FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 43:27CrossRef

25.

Horimoto Y, Arakawa A, Harada-Shoji N, Sonoue H, Yoshida Y, Himuro T et al (2015) Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases. Br J Cancer 112:345–351CrossRef

26.

Himuro T, Horimoto Y, Arakawa A, Matsuoka J, Tokuda E, Tanabe M et al (2016) Activated caspase 3 expression in remnant disease after neoadjuvant chemotherapy may predict outcomes of breast cancer patients. Ann Surg Oncol. 2016:1–7

27.

Mihály Z, Kormos M, Lánczky A, Dank M, Budczies J, Szász MA et al (2013) A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. Breast Cancer Res Treat 140:219–232CrossRef

28.

Kennecke H, Olivotto I, Speers C, Norris B, Chia S, Bryce C et al (2006) Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 18:45–51CrossRef

29.

Hampsch RA, Wells JD, Traphagen NA, McCleery CF, Fields JL, Shee K et al (2020) AMPK activation by metformin promotes survival of dormant ER+ breast cancer cells. Clinical Cancer Res. https://doi.org/10.1158/1078-0432.CCR-20-0269 CrossRef

30.

Ogba N, Manning NG, Bliesner BS, Ambler SK, Haughian JM, Pinto MP et al (2014) Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells. Breast Cancer Res 16:489CrossRef

31.

Sansone P, Savini C, Kurelac I, Chang Q, Amato LB, Strillacci A et al (2017) Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. Proc Natl Acad Sci USA 114:E9066–E9075CrossRef

32.

Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM et al (2013) Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. Breast Cancer Res 15:R86CrossRef

33.

Bense RD, Qiu S-Q, de Vries EGE, Schröder CP, Fehrmann RSN (2018) Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer. Cancer Treat Rev 70:118–126CrossRef

34.

Zhang Y, Schroeder BE, Jerevall P-L, Ly A, Nolan H, Schnabel CA et al (2017) A novel breast cancer index for prediction of distant recurrence in HR⁺ early-stage breast cancer with one to three positive nodes. Clin Cancer Res 23:7217–7224CrossRef

35.

Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K et al (2016) Comparison of EndoPredict and EPclin with oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst 108:149CrossRef

Titel: High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer
verfasst von: Yoshiya Horimoto
Noriko Sasahara
Ritsuko Sasaki
May Thinzar Hlaing
Asumi Sakaguchi
Harumi Saeki
Atsushi Arakawa
Takanori Himuro
Mitsue Saito
Publikationsdatum: 22.06.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05751-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer

Impact of NR5A2 and RYR2 3′UTR polymorphisms on the risk of breast cancer in a Chinese Han population

Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer

CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA

Use of MarginProbe as an adjunct to standard operating procedure does not significantly reduce re-excision rates in breast conserving surgery

Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie